Results from a recent study are likely to help improve the diagnosis and treatment of allergies, pointing to a potential marker of these conditions and a new therapeutic strategy.
The study was led by investigators at Massachusetts General Hospital and the results was published in Nature.
Certain antibodies — called IgE antibodies — bind to allergens such as peanuts and trigger a reaction that releases an array of molecules that cause allergic symptoms, and in extreme cases, potentially life-threatening anaphylaxis.
Scientists have been perplexed by the fact that many individuals have circulating allergen-specific IgE antibodies without ever developing allergy symptoms.
For example, about half of the people who have peanut-specific IgE antibodies (or test positive to a peanut skin prick test) do not have peanut allergies.
In addition, some allergic individuals outgrow their symptoms yet still retain detectable levels of circulating allergen-specific IgE.
To look into these mysteries, Robert Anthony, PhD, of the Center for Immunology and Inflammatory Diseases, and his colleagues compared IgE from individuals with peanut allergies with IgE from individuals without any allergies.
The analyses revealed an increase in a particular sugar residue called sialic acid on IgE from peanut-allergic individuals.
The researchers also found that adding sialic acid to IgE enhanced allergic reactions triggered by IgE in animal models while removing sialic acid from IgE dampened these reactions and reduced anaphylaxis.
“Our results indicate that quantifying sialic acid on IgE may serve as a marker for more accurate diagnoses of allergic disease, and that removal of sialic acid from IgE is a novel strategy for treating affected patients,” said Dr Anthony. (ANI)
